Cerebrolysin
FPF-1070
A porcine-brain-derived peptide mixture studied in humans for stroke, dementia, and traumatic brain injury.
Class
Neuropeptide preparation (porcine brain-derived)
Half-life
Variable (peptide mixture)
Evidence
Limited human data
Limited human data
Small open-label studies, case series, or trials in a narrow population. Directionally informative, not conclusive.
Overview
Cerebrolysin is not a single peptide but a standardised mixture of low-molecular-weight peptides and amino acids derived from purified pig brain. It is used clinically in a number of countries (though not the US) for stroke, vascular dementia, Alzheimer's, and traumatic brain injury, and it has a larger human trial base than most single research peptides.
It is proposed to act like a cocktail of neurotrophic factors, supporting neuronal survival, plasticity, and repair. Meta-analyses of its stroke and dementia trials show modest benefit on some cognitive and functional endpoints, though trial quality is variable and results are debated.
It is administered intravenously or intramuscularly in a clinical setting, not self-injected subcutaneously like most peptides here, and its biological-source nature means batch consistency and infection screening matter. It is not FDA approved.
How it works
- Acts as a mixture mimicking endogenous neurotrophic factors (neurotrophic-like activity).
- Supports neuronal survival, differentiation, and synaptic plasticity.
- Reduces excitotoxicity and apoptosis in ischemia models.
- Modulates neuroinflammation.
What the research shows
Researched effects
- Modest benefit on cognitive and functional endpoints in stroke and dementia meta-analyses
- Reported benefit in traumatic brain injury recovery
- Neuroprotection in animal ischemia models
- Larger human trial base than most single research peptides
Limitations & what it won't do
- Trial quality is variable; benefit is modest and contested.
- Biological (porcine) source raises batch-consistency and screening concerns.
- Requires IV/IM administration in a clinical setting.
- Not FDA approved.
Dosing protocols
These ranges reflect published trials and community protocols. They are reference information, not a prescription. Doses are per injection unless noted.
Clinical course (reference)
5–30 mL of solutionAdministered clinically, not as a self-injected subcutaneous peptide. Dose depends on indication and is a clinician's decision.
Administration
Not an injectable reconstitution compound
Side effects
Common
- Injection-site reactions
- Dizziness
- Flushing
- Agitation with rapid infusion
Serious / rare
- Hypersensitivity/allergic reactions to the porcine-derived material
- Seizures reported rarely
Contraindications & interactions
Do not use if you have
- Pregnant, breastfeeding, or trying to conceive
Not recommended in pregnancy.
- Seizure disorder
Rare seizure reports; a seizure disorder is a contraindication.
Use caution if you have
- Kidney disease
Severe renal impairment is a caution per its clinical labelling.
- Autoimmune condition
Biological-source material can provoke immune reactions.
Medication interactions
- avoidMAO inhibitors — Clinical labelling warns against concurrent MAOI use.
- cautionSSRIs / SNRIs — Combining with antidepressants is not well characterised.
What to monitor
- Allergic response
- Neurological status
References
Research & educational information only — not medical advice.
You must be 18 or older to use this site. The peptides described are presented as research chemicals intended for research purposes only. Most are not approved by the FDA for human use. Dosing ranges reflect what has appeared in the scientific literature or community protocols and are not prescriptions. Nothing here replaces evaluation by a licensed physician who knows your full medical history.
Want to know if Cerebrolysin fits your goals and history?
The assessment cross-checks your medical history and medications against this and every other compound before it recommends anything.
Start the assessment